Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib plus hepatic arterial infusion FOLFOX in intermediate-stage HCC beyond Up-To-Seven criteria
ChiCTR2100045241Phase 2Recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: Objective response rate. Started Apr 2021; status: recruiting.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100045241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045241.